Top Markets
#1 Purr Purr +51.58%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 ApeX ApeX +22.50%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +21.92%
#5 Non-Playable Coin Non-Playable Coin +20.38%
#6 OriginTrail OriginTrail +19.93%
#7 龙虾 (Lobster) 龙虾 (Lobster) +19.21%
#8 Zora Zora +17.21%
#9 Pons Pons +16.45%
#10 Pendle Pendle +16.17%
Coin of the day
Purr Purr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Classement en actions #21772
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Prix de l'action
$1.11
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$100.55M
Changement (1 jour)
-7.69%
Changement (1 an)
-7.17%
Pays
TW
Échange Senhwa Biosciences, Inc. (6492)

Catégorie

Healthcare
Bénéfices pour Senhwa Biosciences, Inc. (6492)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Senhwa Biosciences, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Senhwa Biosciences, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH